AcariaHealth is proud to partner with Gilead Sciences, Inc. to help bring hope to patients living with PBC. We are now dispensing LIVDELZI® (seladelpar) -  an oral, once-daily therapy for adults withPBC and inadequate response or intolerance to ursodeoxycholic acid (UDCA).

As the first and only PPAR delta agonist approved for PBC, LIVDELZI provides a novel mechanism to address disease progression and enhance quality of life.

LIVDELZI: New Hope for PBC Patients

Primary biliary cholangitis (PBC) is a rare, chronic autoimmune disease that gradually damages the bile ducts in the liver. Over time, this damage can lead to inflammation, scarring, and eventually liver failure, if left untreated.

PBC affects an estimated 130,000 people in the U.S., predominantly women. Common early symptoms include fatigue and persistent itching (pruritus), which can severely disrupt daily life and sleep patterns.

While there is no cure for PBC, early diagnosis and effective treatment can help slow liver damage and manage symptoms. By addressing both disease progression and quality-of-life impacts, LIVDELZI offers patients a more manageable treatment journey.

Personalized Support You Can Count On

At AcariaHealth, we understand the challenges of living with a rare, chronic condition. That’s why we offer more than medication access: we combine compassion, reliability, and clinical excellence.

With LIVDELZI now available through our pharmacy, patients can count on:

• Expert guidance through onboarding and initiation
• Reliable medication delivery, when and where it’s needed
• Ongoing personalized support to help patients stay on track

Learn More

Explore more information and resources, visit:

• livdelzi.com – For patients and families
• livdelzihcp.com – For healthcare professionals

Stay informed on the latest in specialty pharmacy by following AcariaHealth on LinkedIn.